[9] Rakesh Kanji, Abhinav Sharma, and Ganesh Bagler. Phenotypic side effects prediction by optimizing correlation with chemical and target profiles of drugs. Molecular BioSystems, 11 (11):2900-2906, 2015.
[10] Brian J Bender, Stefan Gahbauer, Andreas Luttens, Jiankun Lyu, Chase M Webb, Reed M Stein, Elissa A Fink, Trent E Balius, Jens Carlsson, John J Irwin, et al. A practical guide to large-scale docking. Nature protocols, 16(10):4799-4832, 2021.
[11] Reed M Stein, Hye Jin Kang, John D McCorvy, Grant C Glatfelter, Anthony J Jones, Tao Che, Samuel Slocum, Xi-Ping Huang, Olena Savych, Yurii S Moroz, et al. Virtual discovery of melatonin receptor ligands to modulate circadian rhythms. Nature, 579(7800):609-614, 2020.
[12] Ralf Mueller, Alice L Rodriguez, Eric S Dawson, Mariusz Butkiewicz, Thuy T Nguyen, Stephen Oleszkiewicz, Annalen Bleckmann, C David Weaver, Craig W Lindsley, P Jeffrey Conn, et al. Identification of metabotropic glutamate receptor subtype 5 potentiators using virtual high-throughput screening. ACS chemical neuroscience, 1(4):288-305, 2010.
[13] Liying Zhang, Denis Fourches, Alexander Sedykh, Hao Zhu, Alexander Golbraikh, Sean Ekins, Julie Clark, Michele C Connelly, Martina Sigal, Dena Hodges, et al. Discovery of novel antimalarial compounds enabled by qsr-based virtual screening. Journal of chemical information and modeling, 53(2):475-492, 2013.
[14] Bruno J Neves, Rafael F Dantas, Mario R Senger, Cleber C Melo-Filho, Walter CG Valente, Ana CM de Almeida, João M Rezende-Neto, Elid FC Lima, Ross Paveley, Nicholas Furnham, et al. Discovery of new anti-schistosomal hits by integration of qsr-based virtual screening and high content screening. Journal of medicinal chemistry, 59(15):7075-7088, 2016.
[15] Georges E Janssens, Xin-Xuan Lin, Lluís Millan-Ariño, Alan Kavšek, Ilke Sen, Renee I Seinstra, Nicholas Stroustrup, Ellen AA Nollen, and Christian G Riedel. Transcriptomics-based screening identifies pharmacological inhibition of hsp90 as a means to defer aging. Cell Reports, 27(2): 467-480, 2019.
[16] Jonathan M Stokes, Kevin Yang, Kyle Swanson, Wengong Jin, Andres Cubillos-Ruiz, Nina M Donghia, Craig R MacNair, Shawn French, Lindsey A Carfrae, Zohar Bloom-Ackermann, et al. A deep learning approach to antibiotic discovery. Cell, 180(4):688-702, 2020.
[17] Zhenqin Wu, Bharath Ramsundar, Evan N Feinberg, Joseph Gomes, Caleb Geniesse, Aneesh S Pappu, Karl Leswing, and Vijay Pande. Molecularnet: a benchmark for molecular machine learning. Chemical science, 9(2):513-530, 2018.
[18] Kexin Huang, Tianfan Fu, Wenhao Gao, Yue Zhao, Yusuf Roohani, Jure Leskovec, Connor W Coley, Cao Xiao, Jimeng Sun, and Marinka Zitnik. Therapeutics data commons: Machine learning datasets and tasks for drug discovery and development. arXiv preprint arXiv:2102.09548, 2021.
[19] Arash Keshavarzi Arshadi, Milad Salem, Arash Firouzbakht, and Jiann Shiun Yuan. Moldata, a molecular benchmark for disease and target based machine learning. Journal of Cheminformatics, 14(1):1-18, 2022.
[20] Yuanfeng Ji, Lu Zhang, Jiaxiang Wu, Bingzhe Wu, Long-Kai Huang, Tingyang Xu, Yu Rong, Lanqing Li, Jie Ren, Ding Xue, et al. Drugood: Out-of-distribution (ood) dataset curator and benchmark for ai-aided drug discovery-a focus on affinity prediction problems with noise annotations. arXiv preprint arXiv:2201.09637, 2022.
[21] Shurui Gui, Xiner Li, Limei Wang, and Shuiwang Ji. Good: A graph out-of-distribution benchmark. arXiv preprint arXiv:2206.08452, 2022.
[22] Ziqiao Zhang, Bangyi Zhao, Ailin Xie, Yatao Bian, and Shuigeng Zhou. Activity cliff prediction: Dataset and benchmark. arXiv preprint arXiv:2302.07541, 2023.
[23] Derek van Tilborg, Alisa Alenicheva, and Francesca Grisoni. Exposing the limitations of molecular machine learning with activity cliffs. Journal of Chemical Information and Modeling, 62(23):5938-5951, 2022.